Cosmo Oil, SBI Alapromo Of Japan And German Drug Co. Establish New JV
This article was originally published in PharmAsia News
Executive Summary
Japan's Cosmo Oil and SBI Alapromo, along with Germany's Medec GmbH, have signed a deal to establish a joint venture to develop new drugs using aminolevulinic acid. To be established in June, the new company ALA Pharma will have €25,000 in capital investment. SBI Alapromo and Medec will each take a 50 percent stake. Medec obtained approval from the European Medicines Agency for Giolan (5-aminolevulinic) for visualization of malignant tissue during surgery for brain tumors. Cosmo Oil owns 15 percent of SBI Alapromo's total shares. (Click here for more - Japanese language
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.